| Nov 14 |
Elicio Therapeutics GAAP EPS of -$1.39
|
| Nov 13 |
Elicio Therapeutics: Q3 Earnings Snapshot
|
| Nov 13 |
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
|
| Oct 31 |
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
|
| Oct 24 |
All You Need to Know About Elicio Therapeutics (ELTX) Rating Upgrade to Strong Buy
|
| Sep 13 |
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
|
| Aug 14 |
Elicio Therapeutics GAAP EPS of -$0.64
|
| Aug 13 |
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
|
| Aug 12 |
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note
|
| Jun 28 |
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
|
